AstraZeneca looks for alliance to share drug development costs, FT says

Reflecting the growing trend for drugmakers to share costs and risks of developing new drugs, AstraZeneca is considering a big strategic alliance with another pharmaceutical company to share the costs and benefits of experimental drug development, the Financial Times says.

View Comments (0)